After reading this note you will be able to recognise, investigate and initiate appropriate management of haemolytic anaemia in Kenyan clinical rotations, while remembering to verify drug choices and local protocols against the Kenya MoH guideline and your hospital formulary.
Definition
Haemolytic anaemia is a reduction in haemoglobin concentration caused by premature destruction of red blood cells (RBCs) either within the circulation (intravascular) or in the reticulo‑endothelial system (extravascular), leading to a compensatory increase in erythropoiesis that is insufficient to maintain normal haematocrit.
Anatomy and physiology you need
| Structure | Relevance to haemolysis |
|---|---|
| RBC membrane | Defects (e.g., hereditary spherocytosis) make cells fragile → splenic sequestration |
| Cytoskeleton (spectrin, ankyrin) | Mutations alter deformability → intravascular rupture |
| Spleen | Primary site of extravascular removal of opsonised or rigid cells |
| Liver (Kupffer cells) | Clears circulating free haemoglobin and damaged cells |
| Bone marrow | Increases erythropoietin‑driven reticulocytosis as compensation |
| Complement system | Auto‑antibody activation can tag RBCs for destruction |
| Haptoglobin & hemopexin | Bind free haemoglobin/heme; depleted in massive intravascular haemolysis |
Causes and risk factors
| Category | Common aetiologies in Kenya |
|---|---|
| Immune‑mediated | Autoimmune haemolytic anaemia (warm IgG, cold IgM), drug‑induced (e.g., penicillins, quinine) |
| Infectious | Malaria (Plasmodium falciparum), HIV‑related immune dysregulation, acute bacterial sepsis (e.g., Clostridium perfringens), TB (rarely) |
| Hemoglobinopathies | Sickle cell disease, thalassaemia intermedia |
| Enzyme deficiencies | G6PD deficiency (triggered by antimalarials, sulfa drugs, fava beans) |
| Membrane disorders | Hereditary spherocytosis, hereditary elliptocytosis |
| Mechanical | Prosthetic heart valves, severe malaria‑induced microvascular obstruction |
| Miscellaneous tropical | Babesiosis (rare), leishmaniasis (splenic sequestration) |
Risk factors specific to our setting include high malaria transmission zones, widespread use of antimalarials and sulfa drugs, HIV prevalence, and consanguinity in certain communities increasing hereditary disorders.
Pathophysiology
- Trigger (auto‑antibody, infection, enzyme deficiency, mechanical stress) →
- RBC injury (membrane loss, oxidative damage, shape change) →
- Recognition by spleen/macrophages or complement →
- Destruction (extravascular phagocytosis or intravascular lysis) →
- Release of haemoglobin → scavenged by haptoglobin (depleted) → free haem → oxidative injury → renal tubular damage →
- Compensatory erythropoiesis (↑ reticulocytes, ↑ erythropoietin) →
- Clinical anaemia when destruction > production.
Clinical features
| Aspect | Key questions / findings | Why it occurs |
|---|---|---|
| Onset & tempo | “When did you first notice symptoms? Sudden vs. gradual?” | Acute hemolysis (e.g., malaria, drug‑induced) gives rapid onset; chronic hemolysis (e.g., sickle cell, hereditary spherocytosis) is insidious. |
| Fever / infection | Recent fever, cough, night sweats, TB exposure, HIV status, malaria travel | Infections can trigger immune hemolysis or cause direct parasite‑mediated RBC destruction. |
| Jaundice | Yellow eyes or skin, dark urine, timing relative to illness | Unconjugated bilirubin rises from rapid breakdown of hemoglobin; urine may be dark from hemoglobinuria. |
| Fatigue & dyspnoea | “Do you feel unusually tired or short‑of‑breath on exertion?” | Anemia reduces oxygen‑carrying capacity; hemolysis also reduces functional RBC mass. |
| Chest pain / palpitations | Chest discomfort, rapid heartbeat | Tissue hypoxia and high-output cardiac state can precipitate angina or arrhythmias. |
| Abdominal pain | Right upper quadrant discomfort, splenomegaly symptoms | Enlarged spleen from sequestration of damaged RBCs can cause pain; hepatic congestion from bilirubin overload. |
| Dark urine / hemoglobinuria | “Is your urine tea‑coloured or reddish?” | Free hemoglobin filtered by kidneys when intravascular hemolysis overwhelms haptoglobin. |
| Pruritus after bathing | “Do you itch after a hot shower?” | Biliary salts from unconjugated bilirubin can deposit in skin, causing cholestatic pruritus. |
| History of drugs / toxins | Recent antibiotics, antimalarials, herbal remedies, quinine, dapsone | Many drugs act as haptens, provoking immune‑mediated RBC destruction. |
| Family history | “Any relatives with anemia, jaundice, gallstones?” | Inherited membrane or enzyme defects (spherocytosis, G6PD deficiency) are familial. |
| Ethnicity / geography | Kenyan, tribal background, residence in malaria‑endemic area | Sickle cell trait, G6PD variants, malaria exposure are more prevalent locally. |
| Past medical history | Known HIV, TB, autoimmune disease, splenectomy | HIV‑associated autoimmune hemolysis; TB drugs (rifampicin) can trigger hemolysis; splenectomy predisposes to certain hemolytic processes. |
Examination findings
- Pallor – reduced hemoglobin from loss of RBCs.
- Jaundice (scleral, skin) – accumulation of unconjugated bilirubin.
- Splenomegaly – hyperactive spleen sequestering and destroying abnormal RBCs; common in hereditary spherocytosis, sickle cell, malaria.
- Hepatomegaly – congestion from bilirubin processing or extramedullary hematopoiesis.
- Gallstones (palpable RUQ mass) – chronic hemolysis → pigment stones.
- Tachycardia – compensatory response to anemia.
- Blood pressure low or orthostatic – severe anemia reduces vascular resistance.
- Peripheral smear clues – spherocytes, bite cells, schistocytes, sickled cells; each reflects a specific mechanism of RBC injury.
- Signs of hemoglobinuria – brown‑black urine on catheter bag, positive dipstick for blood without RBCs.
- Neurological signs – confusion or seizures in severe anemia or massive hemolysis (cerebral hypoxia).
Differential diagnosis
| Condition | Points toward it | How to separate |
|---|---|---|
| Autoimmune hemolytic anemia (AIHA) | Positive Coombs, associated autoimmune disease, drug exposure | Direct antiglobulin test positive; warm vs. cold antibodies; no enzyme deficiency. |
| G6PD deficiency | Male, African descent, oxidative drug/food trigger, episodic hemolysis | Bite cells & Heinz bodies on smear; normal Coombs; enzyme assay low. |
| Sickle cell disease / trait | Afro‑Kenyan, pain crises, splenomegaly early, dactylitis | Sickled cells on smear; Hb electrophoresis shows HbS. |
| Malaria‑induced hemolysis | Recent fever, travel to endemic area, positive rapid test | Parasites seen on thick/thin smear; rapid resolution with antimalarials. |
| Hereditary spherocytosis | Family history, splenomegaly, gallstones, spherocytes | Osmotic fragility test abnormal; negative Coombs. |
| Thrombotic microangiopathy (TTP/HUS) | Neurologic changes, renal impairment, fever, thrombocytopenia | Schistocytes on smear; low ADAMTS13 (TTP); renal labs. |
| Drug‑induced immune hemolysis | Recent quinine, penicillin, cephalosporin, dapsone | Coombs positive with drug‑dependent antibodies; resolves after drug withdrawal. |
| Hemoglobinopathies (e.g., thalassemia) | Microcytic anemia, target cells, family history | Hemoglobin electrophoresis abnormal; no hemolysis markers unless severe. |
Investigations
| Test | What it answers | Interpretation |
|---|---|---|
| Full blood count with reticulocyte count | Anemia severity, marrow response | Low Hb + high retic = hemolysis; low retic suggests marrow failure. |
| Peripheral blood smear | Morphology of RBCs | Spherocytes → hereditary spherocytosis/AIHA; bite cells → G6PD; schistocytes → TMA; sickle cells → sickle disease. |
| Direct antiglobulin test (DAT/Coombs) | Immune vs. non‑immune hemolysis | Positive = AIHA or drug‑induced immune; negative points to non‑immune causes. |
| Serum bilirubin (total & direct) | Unconjugated vs. conjugated rise | Predominantly indirect ↑ → hemolysis; direct ↑ suggests hepatic obstruction. |
| Lactate dehydrogenase (LDH) | Cell turnover | Markedly elevated in hemolysis; normal in anemia of chronic disease. |
| Haptoglobin | Free hemoglobin binding capacity | Low/undetectable in intravascular hemolysis; normal in extravascular. |
| Urine dipstick for blood & microscopy | Hemoglobinuria vs. hematuria | Positive dipstick, no RBCs → hemoglobinuria (intravascular). |
| G6PD assay | Enzyme deficiency | Low activity confirms G6PD deficiency; avoid oxidative drugs. |
| Hemoglobin electrophoresis / HPLC | Hemoglobin variants | Detects HbS, HbC, HbF elevations; confirms sickle cell or thalassemia. |
| Malaria rapid diagnostic test / thick smear | Parasite presence | Positive → malaria‑related hemolysis; treat accordingly. |
| HIV serology & viral load | Underlying infection | HIV can cause immune hemolysis; antiretroviral therapy needed. |
| TB screening (GeneXpert, sputum) | Co‑existing infection | TB drugs may precipitate hemolysis; treat TB concurrently. |
| ADAMTS13 activity (if TMA suspected) | Distinguish TTP | Severely reduced activity supports TTP; requires plasma exchange. |
Diagnosis and severity
- Confirm hemolysis – combination of anemia, reticulocytosis, elevated LDH, indirect bilirubin, low haptoglobin, and smear findings.
- Classify mechanism – immune (DAT +), enzymatic (G6PD low), membrane (spherocytes, osmotic fragility), hemoglobinopathy (electrophoresis), infectious (malaria smear), or microangiopathic (schistocytes, low platelets).
- Assess severity –
- Mild: Hb > 10 g/dL, stable vitals, no organ dysfunction.
- Moderate: Hb 8‑10 g/dL, tachycardia, mild jaundice, no renal failure.
- Severe/critical: Hb < 8 g/dL, hypotension, acute renal injury, high LDH > 2‑3× upper limit, marked bilirubin, signs of heart failure or cerebral hypoxia.
- Stage for management – Immediate stabilization for severe/critical (oxygen, transfusion, treat underlying trigger). Definitive therapy directed at the identified mechanism (immunosuppression for AIHA, avoidance of oxidants for G6PD, antimalarials for malaria, splenectomy for hereditary spherocytosis when indicated, plasma exchange for TTP).
Severity guides urgency of transfusion, need for intensive monitoring, and whether adjunctive therapies (e.g., steroids, rituximab, IVIG) are required. Continuous reassessment with repeat Hb, LDH, and clinical status is essential.
Management
Immediate stabilisation
| Issue | Action | Rationale |
|---|---|---|
| Severe anaemia (Hb < 6 g/dL) | Transfuse packed red cells (type‑specific, cross‑matched) | Restores oxygen‑carrying capacity; avoid over‑transfusion in chronic hemolysis |
| Acute hemolysis with renal risk | Give isotonic IV fluids (e.g., normal saline) ± diuretics if oliguric | Prevents pigment nephropathy; maintain urine output |
| Hyperbilirubinaemia with risk of kernicterus (neonate) | Phototherapy or exchange transfusion as per protocol | Reduces unconjugated bilirubin load |
| Severe thrombocytopaenia or coagulopathy | Replace platelets / fresh frozen plasma if bleeding | Controls hemorrhagic complications |
| Hypotension/shock | Fluid resuscitation, vasopressors if needed | Maintains perfusion to vital organs |
Definitive treatment – directed at the underlying cause
| Underlying cause | First‑line therapy (drug class) | Adjuncts / special considerations |
|---|---|---|
| Autoimmune (warm) AIHA | Corticosteroids (e.g., prednisolone) | Taper once Hb stabilises; consider rituximab if refractory |
| Autoimmune (cold) AIHA | Avoid cold exposure; rituximab ± complement inhibitor | Splenectomy rarely needed |
| Hereditary spherocytosis / G6PD deficiency | Folate supplementation; splenectomy for spherocytosis if symptomatic | Avoid oxidant drugs, infections, and certain foods in G6PD |
| Sickle cell disease with hemolysis | Hydroxyurea (disease‑modifying) + analgesia; consider chronic transfusion program | Vaccinate against encapsulated organisms; penicillin prophylaxis in children |
| Malaria‑induced hemolysis | Artemisinin‑based combination therapy (ACT) | Treat concurrently for anemia; monitor for delayed hemolysis |
| HIV‑associated hemolysis | Optimise antiretroviral therapy; treat opportunistic infections | Screen for drug‑induced hemolysis (e.g., TMP‑SMX) |
| TB‑associated hemolysis | Standard anti‑TB regimen; corticosteroids if immune‑mediated | Monitor liver function; avoid hemolytic drugs |
| Paroxysmal nocturnal hemoglobinuria | Eculizumab (complement inhibitor) or ravulizumab | Vaccinate against meningococcus before start |
| Drug‑induced immune hemolysis | Discontinue offending drug | Supportive transfusion if needed |
Monitoring & follow‑up
- Daily Hb, reticulocyte count, LDH, bilirubin until stable.
- Renal function (creatinine, urine output) every 24 h in acute hemolysis.
- Screen for allo‑antibodies before each transfusion.
- For chronic conditions (e.g., AIHA, hereditary spherocytosis) review every 3‑6 months; assess splenomegaly, bone density (steroids), and iron overload (ferritin, MRI).
- Patient education: avoid triggers (cold, oxidant drugs), recognize worsening jaundice or dark urine, and adhere to prophylactic vaccines.
Contra‑indications & safety
- Splenectomy contraindicated in active infection or severe thrombocytopaenia.
- Corticosteroids contraindicated in uncontrolled diabetes, active severe infection without coverage.
- Complement inhibitors require meningococcal vaccination; avoid in patients with unresolved meningococcal infection.
- Blood transfusion: avoid in patients with known severe allo‑antibody mediated hemolysis unless lifesaving; use washed cells if IgG‑mediated.
Complications and prognosis
| Complication | Mechanism | Clinical impact |
|---|---|---|
| Iron overload | Repeated transfusions → excess iron deposition | Cardiac failure, hepatic cirrhosis, endocrine dysfunction; monitor ferritin, consider chelation |
| Pigment nephropathy | Hemoglobin casts obstruct tubules | Acute kidney injury; may need dialysis |
| Gallstones (pigment) | Chronic bilirubin excess | Biliary colic, cholangitis; ultrasound screening in chronic hemolysis |
| Aplastic crisis | Parvovirus B19 infection in patients with high turnover | Sudden severe anemia; supportive transfusion |
| Thromboembolism | Hyper‑coagulable state in hemolysis (free hemoglobin scavenges NO) | Deep vein thrombosis, pulmonary embolism; consider prophylaxis in high‑risk |
| Splenic sequestration (sickle cell) | Acute splenic pooling of blood | Rapid drop in Hb, hypovolaemia; emergency transfusion & splenectomy if recurrent |
| Autoimmune hemolysis relapse | Inadequate immunosuppression | Chronic morbidity; requires long‑term monitoring |
Prognosis depends on cause:
- AIHA: good with steroids/rituximab, poorer if refractory.
- Hereditary spherocytosis: excellent after splenectomy.
- Sickle cell: variable; disease‑modifying therapy improves survival.
- PNH: markedly improved with complement inhibitors; otherwise high risk of thrombosis.
High‑yield exam points
- Look‑alikes: differentiate AIHA (positive DAT) from hereditary hemolysis (negative DAT, family history, smear).
- Common wrong first step: giving iron supplements in hemolytic anemia – iron is usually normal or high; may worsen iron overload.
- Bedside examiner question: “Explain why the patient’s urine is dark and what you would do about it.” (Answer: hemoglobinuria from intravascular hemolysis; ensure adequate hydration, monitor renal function, avoid nephrotoxic drugs).
- Key exam fact: In warm AIHA the direct Coombs test is usually IgG‑positive; in cold AIHA it is C3‑positive.
- Trigger avoidance: For G6PD deficiency, list three common oxidant drugs (e.g., sulfonamides, quinine, dapsone).
- Transfusion safety: Always cross‑match and consider washed cells in IgG‑mediated hemolysis.
Clinical case
Case: A 28‑year‑old Kenyan male presents with 5 days of fatigue, jaundice, and dark urine. He is HIV‑positive on ART, CD4 = 350 cells/µL. Examination: scleral icterus, mild splenomegaly, no fever. Labs: Hb 7.2 g/dL, retic 8 %, LDH 850 U/L, indirect bilirubin 4 mg/dL, DAT positive for IgG.
Questions
- What is the most likely diagnosis?
Warm autoimmune hemolytic anemia (AIHA) secondary to HIV.
- What is the immediate management step?
Transfuse type‑specific packed red cells if symptomatic, start IV fluids, and begin high‑dose oral corticosteroids.
- Which long‑term therapy should be considered if the patient does not respond to steroids within 4 weeks?
Rituximab (anti‑CD20 monoclonal antibody) as second‑line immunosuppression.
Practice questions
Question 1
A 5‑year‑old child from a malaria‑endemic area presents with pallor, jaundice, and a hemoglobin of 5 g/dL after a recent bout of fever. Smear shows Plasmodium falciparum. What is the next best step?
A. Immediate splenectomy
B. Start artemisinin‑based combination therapy and give a packed red cell transfusion
C. Give oral iron supplements
D. Begin high‑dose steroids
Answer: B. Start artemisinin‑based combination therapy and give a packed red cell transfusion
Explanation: Treat the underlying malaria promptly; severe anemia warrants transfusion.
Question 2
A 40‑year‑old woman with known hereditary spherocytosis presents with worsening anemia (Hb 6 g/dL) but a negative direct Coombs test. Which feature helps distinguish her condition from warm AIHA?
A. Presence of spherocytes on peripheral smear
B. Positive DAT for IgG
C. Elevated serum ferritin
D. Low reticulocyte count
Answer: A. Presence of spherocytes on peripheral smear
Explanation: Spherocytes are characteristic of hereditary spherocytosis; AIHA may also have spherocytes but DAT positivity differentiates.
Question 3
A patient with PNH develops a new deep‑vein thrombosis despite anticoagulation. Which therapy is indicated to reduce further thrombotic risk?
A. High‑dose vitamin B12
B. Eculizumab (complement inhibitor)
C. Hydroxyurea
D. Splenectomy
Answer: B. Eculizumab (complement inhibitor)
Explanation: Complement blockade reduces hemolysis and thrombotic risk in PNH.
Question 4
A 30‑year‑old man with sickle cell disease presents with acute chest pain, dyspnoea, and a drop in Hb from 9 g/dL to 6 g/dL. Which intervention is most appropriate?
A. Immediate exchange transfusion
B. Oral iron therapy
C. High‑dose corticosteroids
D. Initiate penicillin prophylaxis
Answer: A. Immediate exchange transfusion
Explanation: Acute sickle‑cell crisis with severe anemia and possible vaso‑occlusion requires rapid reduction of Hb S via exchange transfusion.
Question 5
During evaluation of hemolytic anemia, the direct Coombs test is negative, bilirubin is predominantly indirect, and the patient reports recent ingestion of primaquine. What is the most likely diagnosis?
A. Warm AIHA
B. G6PD deficiency–induced hemolysis
C. Paroxysmal nocturnal hemoglobinuria
D. Thalassemia major
Answer: B. G6PD deficiency–induced hemolysis
Explanation: Oxidant drug exposure in G6PD deficiency causes intravascular hemolysis with a negative DAT.
Drafted with AI assistance from standard references and reviewed for structure. Check details against your lecture notes and the Kenya MoH guideline.